^
    10d
    KEYMAKER-06C: Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2029 --> Sep 2029 | Trial primary completion date: Jan 2027 --> Sep 2029
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan) • levoleucovorin calcium
    25d
    KEYMAKER-U06 Substudy 06E: Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (clinicaltrials.gov)
    P1/2, N=298, Recruiting, Merck Sharp & Dohme LLC | N=228 --> 298
    Enrollment change
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • ifinatamab deruxtecan (DS-7300) • Jiataile (sacituzumab tirumotecan) • levoleucovorin calcium
    2ms
    A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov)
    P3, N=477, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Aug 2029 --> Mar 2029
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • calderasib (MK-1084) • levoleucovorin calcium
    2ms
    Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo). (PubMed, Jpn J Clin Oncol)
    FOLFIRI with low-dose irinotecan plus RAM is a feasible second-line treatment in Japanese patients with mCRC.
    P2 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • 5-fluorouracil • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • levoleucovorin calcium
    2ms
    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) (clinicaltrials.gov)
    P3, N=863, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jan 2027 --> Jun 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • paclitaxel • 5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin • levoleucovorin calcium
    3ms
    An open-label, multicenter Phase Ib/II clinical study on the safety, tolerability, pharmacokinetics, and efficacy of QLC5508 injection combined therapy in patients with advanced solid tumors (ChiCTR2500110587)
    P1/2, N=414, Not yet recruiting, Shanghai East Hospital; Qilu Pharmaceutical Co.
    New P1/2 trial
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • MHB088C • levoleucovorin calcium
    5ms
    Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, Taiho Oncology, Inc. | Trial primary completion date: Jul 2025 --> Mar 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • oxaliplatin • Lytgobi (futibatinib) • irinotecan • levoleucovorin calcium
    6ms
    KEYMAKER-U06 Substudy 06E: Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (clinicaltrials.gov)
    P1/2, N=228, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | Trial completion date: Feb 2031 --> Jan 2032 | Trial primary completion date: Feb 2031 --> Jan 2032
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • ifinatamab deruxtecan (DS-7300) • levoleucovorin calcium
    6ms
    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) (clinicaltrials.gov)
    P3, N=863, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jan 2027 --> May 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • paclitaxel • 5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin • levoleucovorin calcium
    6ms
    BREAKWATER: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=831, Active, not recruiting, Pfizer | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Khapzory (levoleucovorin) • levoleucovorin calcium
    6ms
    A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov)
    P3, N=477, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2031 --> Oct 2030
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • calderasib (MK-1084) • levoleucovorin calcium
    6ms
    A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov)
    P3, N=477, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • calderasib (MK-1084) • levoleucovorin calcium